Fixed-Dose combination of the inhaled corticosteroid and long-acting beta₂-agonist therapy in adults with persistent asthma

References

• Holgate ST. A look at the pathogenesis of asthma: the need for a change in direction. Discov Med. 2010 May;9(48):439–447.
   PubMedGoogle Scholar
• Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011 Feb 19;377(9766):650–657.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Barnes PJ. New perspectives in pharmacological treatment of mild persistent asthma. Drug Discov Today. 2011 Dec;16(23–24):1084–1091.
   PubMed Web of Science ®Google Scholar
• Montuschi P. Pharmacotherapy of patients with mild persistent asthma: strategies and unresolved issues. Front Pharmacol. 2011;2:35.
   PubMed Web of Science ®Google Scholar
• From the Global Strategy for Asthma Management and Prevention [Internet]. 2015. Global Initiative for Asthma (GINA). [cited 2015 Dec 1]. Available from: www.ginasthma.org
   Google Scholar
• From National Heart Lung and Blood Institute. 2007. Expert panel report 3: guidelines for the diagnosis and management of asthma [Internet]. National Asthma Education and Prevention Program. [cited 2015 Dec 1]. Available from: www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf
   Google Scholar
• Kroegel C. Global Initiative for Asthma (GINA) guidelines: 15 years of application. Expert Rev Clin Immunol. 2009 May;5(3):239–249.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Pagliari G, Fuso L. Pharmacotherapy of asthma: regular treatment or on demand? Ther Adv Respir Dis. 2009 Aug;3(4):175–191.
   PubMedGoogle Scholar
• Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med. 2007 Dec;101(12):2437–2446.
   PubMed Web of Science ®Google Scholar
• Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract. 2007 May;61(5):725–736.
   PubMed Web of Science ®Google Scholar
• Lazarus SC, Boushey HA, Fahy JV, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001 May 23–30;285(20):2583–2593.
   PubMed Web of Science ®Google Scholar
• Kramer JM. Balancing the benefits and risks of inhaled long-acting beta-agonists–the influence of values. N Engl J Med. 2009 Apr 16;360(16):1592–1595.
   PubMed Web of Science ®Google Scholar
• Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N Engl J Med. 2010 Apr 1;362(13):1169–1171.
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997 Nov 13;337(20):1405–1411.
   PubMed Web of Science ®Google Scholar
• Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med. 1996 May;153(5):1481–1488.
   PubMed Web of Science ®Google Scholar
• Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994 Jul 23;344(8917):219–224.
   PubMed Web of Science ®Google Scholar
• Matsuse H, Kohno S. Leukotriene receptor antagonists pranlukast and montelukast for treating asthma. Expert Opin Pharmacother. 2014 Feb;15(3):353–363.
   PubMed Web of Science ®Google Scholar
• Montuschi P. Leukotrienes, antileukotrienes and asthma. Mini Rev Med Chem. 2008 Jun;8(7):647–656.
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J. 2002 Jan;19(1):182–191.
   PubMed Web of Science ®Google Scholar
• Cheung D, Timmers MC, Zwinderman AH, et al. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992 Oct 22;327(17):1198–1203.
   PubMed Web of Science ®Google Scholar
• Mak JC, Nishikawa M, Shirasaki H, et al. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors in vivo. J Clin Invest. 1995 Jul;96(1):99–106.
   PubMed Web of Science ®Google Scholar
• Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol. 1995 Jan;268(1 Pt 1):L41–46.
   PubMed Web of Science ®Google Scholar
• Adcock IM, Stevens DA, Barnes PJ. Interactions of glucocorticoids and beta 2-agonists. Eur Respir J. 1996 Jan;9(1):160–168.
   PubMed Web of Science ®Google Scholar
• Baraniuk JN, Ali M, Brody D, et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med. 1997 Feb;155(2):704–710.
   PubMed Web of Science ®Google Scholar
• Usmani OS, Ito K, Maneechotesuwan K, et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med. 2005 Sep 15;172(6):704–712.
   PubMed Web of Science ®Google Scholar
• Haque R, Hakim A, Moodley T, et al. Inhaled long-acting β2 agonists enhance glucocorticoid receptor nuclear translocation and efficacy in sputum macrophages in COPD. J Allergy Clin Immunol. 2013 Nov;132(5):1166–1173.
   PubMed Web of Science ®Google Scholar
• Roth M, Johnson PR, Rudiger JJ, et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet. 2002 Oct 26;360(9342):1293–1299.
   PubMed Web of Science ®Google Scholar
• Kaur M, Chivers JE, Giembycz MA, et al. Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol. 2008 Jan;73(1):203–214.
   PubMed Web of Science ®Google Scholar
• Lovén J, Svitacheva N, Jerre A, et al. Anti-inflammatory activity of beta2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor. Eur Respir J. 2007 Nov;30(5):848–856.
   PubMed Web of Science ®Google Scholar
• Raissy HH, Kelly HW, Harkins M, et al. Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med. 2013 Apr 15;187(8):798–803.
   PubMed Web of Science ®Google Scholar
• Leach CL, Davidson PJ, Hasselquist BE, et al. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med. 2005 Winter;18(4):379–385.
   PubMedGoogle Scholar
• Kelly HW. Comparison of inhaled corticosteroids: an update. Ann Pharmacother. 2009 Mar;43(3):519–527.
   PubMed Web of Science ®Google Scholar
• Leach CL, Colice GL. A pilot study to assess lung deposition of HFA-beclomethasone and CFC-beclomethasone from a pressurized metered dose inhaler with and without add-on spacers and using varying breathhold times. J Aerosol Med Pulm Drug Deliv. 2010 Dec;23(6):355–361.
   PubMed Web of Science ®Google Scholar
• Leach CL, Kuehl PJ, Chand R, et al. Respiratory tract deposition of HFA-beclomethasone and HFA-fluticasone in asthmatic patients. J Aerosol Med Pulm Drug Deliv. 2015 Jun 10. [Epub ahead of print]. doi:10.1089/jamp.2014.1199.
   Web of Science ®Google Scholar
• Valotis A, Hogger P. Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res. 2007;8:54.
   PubMed Web of Science ®Google Scholar
• Tamm M, Richards DH, Beghe B, et al. Inhaled corticosteroid and long-acting beta2-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med. 2012 Dec;106(Suppl 1):S9–19.
   Web of Science ®Google Scholar
• Beclometasone dipropionate [Internet]. New Zealand drug data sheet. 2009. [cited 2015 Dec 1]. Available from: www.medsafe.govt.nz/profs/datasheet/b/BeclazoneCFCinh.pdf
   Google Scholar
• QVAR™ INHALER [Internet]. New Zealand drug data sheet 2015. [cited 2015 Dec 1]. Available from: www.medsafe.govt.nz/profs/Datasheet/q/qvarinhaler.pdf
   Google Scholar
• SERETIDE® Inhaler [Internet]. New Zealand drug data sheet. 2015. [cited 2015 Dec 1]. Available from: www.medsafe.govt.nz/profs/datasheet/s/Seretideinh.pdf
   Google Scholar
• SYMBICORT® [Internet]. New Zealand drug data sheet. 2015. [cited 2015 Dec 1]. Available from: www.medsafe.govt.nz/profs/datasheet/s/Symbicortinh.pdf
   Google Scholar
• PULMICORT TURBUHALER [Internet]. New Zealand drug data sheet. 2015. [cited 2015 Dec 1]. Available from: www.medsafe.govt.nz/profs/datasheet/p/Pulmicortturbuhaler.pdf
   Google Scholar
• Frampton JE. Mometasone/formoterol inhalation aerosol: in asthma uncontrolled on medium- or high-dose inhaled corticosteroids. Drugs. 2012 Jun 18;72(9):1229–1241.
   PubMed Web of Science ®Google Scholar
• BREO® ELLIPTA® powder for inhalation [Internet]. New Zealand drug data sheet. 2015. [cited 2015 Dec 1]. Available from: www.medsafe.govt.nz/Profs/Datasheet/b/breoelliptainhalation.pdf
   Google Scholar
• DULERA® prescribing information [Internet]. 2015. [cited 2015 Dec 1]. Available from: www.merck.com/product/usa/pi_circulars/d/dulera/dulera_pi.pdf
   Google Scholar
• Leach CL, Kuehl PJ, Chand R, et al. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol. 2012 Mar;108(3):195–200.
   PubMed Web of Science ®Google Scholar
• Rohatagi S, Appajosyula S, Derendorf H, et al. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol. 2004 Jan;44(1):37–47.
   PubMed Web of Science ®Google Scholar
• Biggadike K. Fluticasone furoate/fluticasone propionate - different drugs with different properties. Clin Respir J. 2011 Jul;5(3):183–184.
   PubMed Web of Science ®Google Scholar
• Biggadike K, Bledsoe RK, Hassell AM, et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J Med Chem. 2008 Jun 26;51(12):3349–3352.
   PubMed Web of Science ®Google Scholar
• Allen A, Bareille PJ, Rousell VM. Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clin Pharmacokinet. 2013 Jan;52(1):37–42.
   PubMed Web of Science ®Google Scholar
• Van Den Berge M, Luijk B, Bareille P, et al. Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with asthma. Allergy. 2010 Dec;65(12):1531–1535.
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bateman ED, Busse WW, et al. Efficacy in asthma of once-daily treatment with fluticasone furoate: a randomized, placebo-controlled trial. Respir Res. 2011;12:132.
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bleecker ER, Busse WW, et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res. 2011;12:160.
   PubMed Web of Science ®Google Scholar
• Busse WW, Bleecker ER, Bateman ED, et al. Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. Thorax. 2012 Jan;67(1):35–41.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Bleecker ER, Lötvall J, et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med. 2012 May;106(5):642–650.
   PubMed Web of Science ®Google Scholar
• Medley H, Orozco S, Allen A. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma. Clin Ther. 2012 Aug;34(8):1683–1695.
   PubMed Web of Science ®Google Scholar
• Bleecker ER, Bateman ED, Busse WW, et al. Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Ann Allergy Asthma Immunol. 2012 Nov;109(5):353–358.e4.
   PubMed Web of Science ®Google Scholar
• Lötvall J, Bleecker ER, Busse WW, et al. Efficacy and safety of fluticasone furoate 100 μg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial. Respir Med. 2014 Jan;108(1):41–49.
   PubMed Web of Science ®Google Scholar
• Woodcock A, Lotvall J, Ww B, et al. Efficacy and safety of fluticasone furoate 100 mug and 200 mug once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. BMC Pulm Med. 2014;14:113.
   PubMed Web of Science ®Google Scholar
• Busse WW, Bateman ED, O’Byrne PM, et al. Once-daily fluticasone furoate 50 mcg in mild-to-moderate asthma: a 24-week placebo-controlled randomized trial. Allergy. 2014 Nov;69(11):1522–1530.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Woodcock A, Bleecker ER, et al. Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. Respir Res. 2014;15:88.
   PubMed Web of Science ®Google Scholar
• Salter M, Biggadike K, Matthews JL, et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol. 2007 Sep;293(3):L660–667.
   PubMed Web of Science ®Google Scholar
• Allen A. The relationship between fluticasone furoate systemic exposure and cortisol suppression. Clin Pharmacokinet. 2013 Oct;52(10):885–896.
   PubMed Web of Science ®Google Scholar
• Van Noord JA, Smeets JJ, Raaijmakers JA, et al. Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J. 1996 Aug;9(8):1684–1688.
   PubMed Web of Science ®Google Scholar
• Palmqvist M, Persson G, Lazer L, et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J. 1997 Nov;10(11):2484–2489.
   PubMed Web of Science ®Google Scholar
• Van Noord JA, Smeets JJ, Maesen FP. A comparison of the onset of action of salbutamol and formoterol in reversing methacholine-induced bronchoconstriction. Respir Med. 1998 Dec;92(12):1346–1351.
   PubMed Web of Science ®Google Scholar
• Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J. 1999 May;13(5):988–992.
   PubMed Web of Science ®Google Scholar
• Palmqvist M, Ibsen T, Mellén A, et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med. 1999 Jul;160(1):244–249.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Ciabattoni G. Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends. J Med Chem. 2015 May 28;58(10):4131–4164.
   PubMed Web of Science ®Google Scholar
• Anderson GP. Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms. Clin Rev Allergy Immunol. 2006 Oct-Dec;31(2–3):119–130.
   PubMed Web of Science ®Google Scholar
• Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013 Apr;26(2):256–264.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Matera MG. β(2) -adrenoceptor agonists: current and future direction. Br J Pharmacol. 2011 May;163(1):4–17.
   PubMed Web of Science ®Google Scholar
• Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs. 2004;64(14):1597–1618.
   PubMed Web of Science ®Google Scholar
• Zetterström O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J. 2001 Aug;18(2):262–268.
   PubMed Web of Science ®Google Scholar
• Bateman ED, Bantje TA, João Gomes M, et al. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am J Respir Med. 2003;2(3):275–281.
   PubMedGoogle Scholar
• Buhl R, Creemers JP, Vondra V, et al. Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma. Respir Med. 2003 Apr;97(4):323–330.
   PubMed Web of Science ®Google Scholar
• Ställberg B, Olsson P, Jörgensen LA, et al. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract. 2003 Oct;57(8):656–661.
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Sears MR, Boulet LP, et al. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J. 2003 Nov-Dec;10(8):427–434.
   PubMedGoogle Scholar
• O’Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med. 2005 Jan 15;171(2):129–136.
   PubMed Web of Science ®Google Scholar
• Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest. 2006 Feb;129(2):246–256.
   PubMed Web of Science ®Google Scholar
• Humbert M, Andersson TL, Buhl R. Budesonide/formoterol for maintenance and reliever therapy in the management of moderate to severe asthma. Allergy. 2008 Dec;63(12):1567–1580.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Barnes NC, Greening AP, et al. Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax. 2010 Aug;65(8):747–752.
   PubMed Web of Science ®Google Scholar
• Nathan RA, Rooklin A, Schoaf L, et al. Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patients with persistent asthma: a randomized, double-blind, placebo-controlled, 12-week study. Clin Ther. 2006 Jan;28(1):73–85.
   PubMed Web of Science ®Google Scholar
• Lemanske RF Jr, Mauger DT, Sorkness CA, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med. 2010 Mar 18;362(11):975–985.
   PubMed Web of Science ®Google Scholar
• Pertseva T, Dissanayake S, Kaiser K. Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial. Curr Med Res Opin. 2013 Oct;29(10):1357–1369.
   PubMed Web of Science ®Google Scholar
• Fabbri LM, Nicolini G, Olivieri D, et al. Inhaled beclometasone dipropionate/formoterol extra-fine fixed combination in the treatment of asthma: evidence and future perspectives. Expert Opin Pharmacother. 2008 Feb;9(3):479–490.
   PubMed Web of Science ®Google Scholar
• Huchon G, Magnussen H, Chuchalin A, et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med. 2009 Jan;103(1):41–49.
   PubMed Web of Science ®Google Scholar
• Price D, Robertson A, Bullen K, et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med. 2010;10:1.
   PubMed Web of Science ®Google Scholar
• Oliver A, Bjermer L, Quinn D, et al. Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination. Allergy. 2013 Sep;68(9):1136–1142.
   PubMed Web of Science ®Google Scholar
• Bateman ED, O’Byrne PM, Busse WW, et al. Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. Thorax. 2014 Apr;69(4):312–319.
   PubMed Web of Science ®Google Scholar
• Lin J, Kang J, Lee SH, et al. Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: a randomized trial. Respir Med. 2015 Jan;109(1):44–53.
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Bleecker ER, Bateman ED, et al. Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. Eur Respir J. 2014 Mar;43(3):773–782.
   PubMed Web of Science ®Google Scholar
• Oliver A, VanBuren S, Allen A, et al. Tolerability of fluticasone furoate/vilanterol combination therapy in children aged 5 to 11 years with persistent asthma. Clin Ther. 2014 Jun 1;36(6):928–939.e1.
   PubMed Web of Science ®Google Scholar
• Svedsater H, Dale P, Garrill K, et al. Qualitative assessment of attributes and ease of use of the ELLIPTA dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013;13:72.
   PubMed Web of Science ®Google Scholar
• Svedsater H, Jacques L, Goldfrad C, et al. Ease of use of the ELLIPTA dry powder inhaler: data from three randomised controlled trials in patients with asthma. NPJ Prim Care Respir Med. 2014;24:14019.
   PubMed Web of Science ®Google Scholar
• Dahl R, Chuchalin A, Gor D, et al. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Respir Med. 2006 Jul;100(7):1152–1162.
   PubMed Web of Science ®Google Scholar
• Busse WW, Shah SR, Somerville L, et al. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. J Allergy Clin Immunol. 2008 Jun;121(6):1407–1414, 14 e1–6.
   PubMed Web of Science ®Google Scholar
• Lasserson TJ, Ferrara G, Casali L. Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev. 2011;(12):CD004106.
   Google Scholar
• Aalbers R, Backer V, Kava TT, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin. 2004;20(2):225–240.
   PubMed Web of Science ®Google Scholar
• Hozawa S, Terada M, Hozawa M. Comparison of the effects of budesonide/formoterol maintenance and reliever therapy with fluticasone/salmeterol fixed-dose treatment on airway inflammation and small airway impairment in patients who need to step-up from inhaled corticosteroid monotherapy. Pulm Pharmacol Ther. 2014 Apr;27(2):190–196.
   PubMed Web of Science ®Google Scholar
• Papi A, Paggiaro PL, Nicolini G, et al. Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J. 2007 Apr;29(4):682–689.
   PubMed Web of Science ®Google Scholar
• Papi A, Paggiaro P, Nicolini G, et al. Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy. 2007 Oct;62(10):1182–1188.
   PubMed Web of Science ®Google Scholar
• Bodzenta-Lukaszyk A, Buhl R, Balint B, et al. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety. J Asthma. 2012 Dec;49(10):1060–1070.
   PubMedGoogle Scholar
• Bodzenta-Lukaszyk A, Dymek A, McAulay K, et al. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med. 2011;11:28.
   PubMed Web of Science ®Google Scholar
• Woodcock A, Bleecker ER, Lotvall J, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest. 2013 Oct;144(4):1222–1229.
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Nicolini G, Bizzi A, et al. Do inhaled corticosteroid/long-acting beta2-agonist fixed combinations provide superior clinical benefits compared with separate inhalers? A literature reappraisal. Allergy Asthma Proc. 2012 Mar-Apr;33(2):140–144.
   PubMed Web of Science ®Google Scholar
• Postma DS, Rabe KF. The Asthma-COPD Overlap Syndrome. N Engl J Med. 2015 Sep 24;373(13):1241–1249.
   PubMed Web of Science ®Google Scholar
• D’Urzo A, Donohue JF, Kardos P, et al. A re-evaluation of the role of inhaled corticosteroids in the management of patients with chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015;16(12):1845–1860.
   PubMed Web of Science ®Google Scholar
• Montuschi P, Malerba M, Santini G, et al. Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today. 2014 Dec;19(12):1928–1935.
   PubMed Web of Science ®Google Scholar
• Malerba M, Radaeli A, Olivini A, et al. The combined impact of exhaled nitric oxide and sputum eosinophils monitoring in asthma treatment: a prospective cohort study. Curr Pharm Des. 2015;21(32):4752–4762.
   PubMed Web of Science ®Google Scholar
• Wu W, Bleecker E, Moore W, et al. Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. J Allergy Clin Immunol. 2014 May;133(5):1280–1288.
   PubMed Web of Science ®Google Scholar